1067 related articles for article (PubMed ID: 15105283)
21. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
Guazzi M; Agostoni P
Clin Sci (Lond); 1999 Jan; 96(1):17-22. PubMed ID: 9857102
[TBL] [Abstract][Full Text] [Related]
22. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
23. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
[TBL] [Abstract][Full Text] [Related]
24. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia.
Costerousse O; Allegrini J; Clozel JP; Ménard J; Alhenc-Gelas F
J Pharmacol Exp Ther; 1998 Mar; 284(3):1180-7. PubMed ID: 9495881
[TBL] [Abstract][Full Text] [Related]
26. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
27. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
Laubie M; Schiavi P; Vincent M; Schmitt H
J Cardiovasc Pharmacol; 1984; 6(6):1076-82. PubMed ID: 6084763
[TBL] [Abstract][Full Text] [Related]
29. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
Tang WH; Vagelos RH; Yee YG; Fowler MB
Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
[TBL] [Abstract][Full Text] [Related]
30. Acute and chronic effects of a novel dihydrobenzofuran analogue and enalapril on blood pressure and plasma and tissue angiotensin converting enzyme activity in the sodium deficient normotensive rat.
Longman SD; Howlett DR
Arzneimittelforschung; 1988 May; 38(5):678-82. PubMed ID: 2843192
[TBL] [Abstract][Full Text] [Related]
31. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
33. Enalapril improves vascular and cardiac function in streptozotocin-diabetic rats.
Crespo MJ; Dunbar DC
Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1311-8. PubMed ID: 14984003
[TBL] [Abstract][Full Text] [Related]
34. [Vasodilator hormonal agents in chronic heart failure: effect of angiotensin-converting enzyme inhibitors].
Godoy I; Corbalán R; Jalil J; Guarda E; Albertini R
Rev Med Chil; 1997 Feb; 125(2):135-42. PubMed ID: 9430932
[TBL] [Abstract][Full Text] [Related]
35. Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans.
Witherow FN; Dawson P; Ludlam CA; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1667-70. PubMed ID: 12869356
[TBL] [Abstract][Full Text] [Related]
36. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin.
Aihara E; Kagawa S; Hayashi M; Takeuchi K
J Physiol Pharmacol; 2005 Sep; 56(3):391-406. PubMed ID: 16204762
[TBL] [Abstract][Full Text] [Related]
37. Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
Fitzpatrick D; Nicholls MG; Ikram H; Espiner EA
J Hypertens Suppl; 1983 Oct; 1(1):147-53. PubMed ID: 6100604
[TBL] [Abstract][Full Text] [Related]
38. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
Erman A; Boner G; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
[TBL] [Abstract][Full Text] [Related]
39. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension.
Fagard R; Lijnen P; Pardaens K; Thijs L; Vinck W
J Hum Hypertens; 2001 Mar; 15(3):161-7. PubMed ID: 11317199
[TBL] [Abstract][Full Text] [Related]
40. The effect of an angiotensin-converting enzyme inhibitor and a K+(ATP) channel opener on warm up angina.
Edwards RJ; Redwood SR; Lambiase PD; Marber MS
Eur Heart J; 2005 Mar; 26(6):598-606. PubMed ID: 15618027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
